A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update

Journal of Internal Medicine - Tập 244 Số 4 - Trang 271-292 - 1998
Richard Eastell1, Donald Reid2, Juliet Compston3, Cyrus Cooper4, I. Fogelman5, Roger M. Francis6, David Hosking7, D.W. Purdie8, Stuart H. Ralston2, J. Reeve3, R.G.G. Russell9, J. Court Stevenson10, David Torgerson11
1University of Sheffield Medical School, UK.
2University of Aberdeen, Aberdeen
3University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge
4Southampton General Hospital, Southampton
5Guy's Hospital, London
6Freeman Hospital Newcastle Upon Tyne
7Nottingham City Hospital, Nottingham
8Hull Royal Infirmary Hull
9University of Sheffield Medical School, Sheffield
10Wynn Institute for Metabolic Research, London
11University of York, York, UK

Tóm tắt

Abstract. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RGG, Stevenson JC, Torgerson DJ (University of Sheffield Medical School, Sheffield; University of Aberdeen, Aberdeen; University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge; Southampton General Hospital, Southampton; Guy's Hospital, London; Freeman Hospital, Newcastle upon Tyne; Nottingham City Hospital, Nottingham; Hull Royal Infirmary, Hull; Wynn Institute for Metabolic Research, London; and the University of York, York, UK). A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update (Review). J Intern Med 1998; 244: 271–292.In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy‐to‐use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day−1 or more for 6 months or more. General measures, e.g. alternative GCs and routes of administration, and therapeutic interventions, e.g. cyclical etidronate and hormone replacement, are recommended.

Từ khóa


Tài liệu tham khảo

10.1111/j.1365-2796.1995.tb00868.x

10.1002/art.1780391104

10.1007/s002239900134

10.1093/rheumatology/36.10.1035

10.1056/NEJM198308043090502

10.1002/art.1780271205

10.1136/ard.54.1.49

10.1210/jcem-52-1-111

10.1136/ard.45.10.852

10.1136/bmj.306.6877.558

10.1136/bmj.312.7041.1254

10.1136/thx.46.11.803

10.1136/ard.54.10.801

10.1056/NEJM199306173282404

10.1002/jbmr.5650051204

10.1007/BF00298431

10.2105/AJPH.85.12.1693

10.1002/jbmr.5650071014

10.1002/art.1780360213

10.1007/BF00675619

10.1016/S0140-6736(94)91049-9

10.1111/j.1432-2277.1995.tb01503.x

Sambrook PN, 1994, Bone loss after heart transplantation: a prospective study., J Heart Lung Transplant, 1, 116

10.1016/S0140-6736(95)92748-4

10.1007/BF01637318

10.1016/0002-9343(94)90113-9

Rich GM, 1992, Cyclosporine A and prednisone‐associated osteoporosis in heart transplant recipients., J Heart Lung Transplant, 11, 950

10.1002/hep.1840140215

Porayko MK, 1991, Bone disease in liver transplant recipients: incidence, timing, and risk factors., Transplant Proc, 23, 1462

10.1136/bmj.309.6961.1069

10.1136/bmj.313.7053.344

10.1136/ard.54.1.66

10.1016/S0300-2977(97)00028-4

10.1111/j.1398-9995.1997.tb05047.x

Aaron JK, 1989, Contrasting microanatomy of idiopathic and corticosteroid‐induced osteoporosis., Clin Orthop Rel Res, 243, 294, 10.1097/00003086-198906000-00044

10.1016/0169-6009(91)90139-Q

10.1016/0221-8747(79)90024-9

10.1007/BF02032284

10.1007/BF02405069

Caporali R, 1991, Serum osteocalcin (bone Gla‐protein) and steroid osteoporosis in rheumatoid arthritis., J Rheumatol, 18, 148

10.1002/jbmr.5650030117

Nielsen HK, 1988, The effects of high‐dose glucocorticoid administration on serum bone gamma carboxyglutamin acid‐containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects., Bone Miner, 4, 105

10.1210/jcem-72-2-382

10.1210/jcem-62-2-379

10.1002/art.1780331005

10.1210/jcem-72-3-530

10.1016/0221-8747(84)90064-X

10.1111/j.1365-2133.1992.tb07816.x

10.1002/jbmr.5650090718

10.1136/gut.29.3.378

Lukert BP Kream BE. Clinical and basic aspects of glucocorticoid action on bone. In: Bilezekian JP Raisz LG Rodan GA edsPrinciples of Bone Biology. San Diego: Academic Press 1996; 533–48.

10.1016/0022-4731(81)90270-3

Gennari C, 1984, Acute changes in urinary radiocalcium following glucocorticoid administration in man., Adv Exp Med Biol, 171, 407

10.1016/S0300-595X(73)80045-3

10.1136/thx.46.3.160

10.1007/s002239900352

10.1136/thx.47.6.414

10.1111/j.1445-5994.1987.tb00064.x

10.1007/BF02561402

Marcus R. Secondary forms of osteoporosis. In: Coe FL Favus NJ eds.Disorders Bone and Mineral Metabolism. New York: Raven Press 1992; 889–904.

Suzuki Y, 1983, Mechanism of development of glucocorticoid‐induced osteoporosis and its treatment. Intestinal calcium absorption and vitamin d metabolism in patients under glucocorticoid therapy and correction of secondary hyperparathyroidism., Nippon Naibunpi Gakkai Zasshi, 59, 918

10.1001/archinte.136.11.1249

10.1210/jcem-40-1-152

10.1016/0049-0172(76)90020-2

10.1007/BF00280099

10.1210/jc.76.2.456

10.7326/0003-4819-112-5-352

Luengo M, 1991, Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment., Eur Resp J, 4, 441, 10.1183/09031936.93.04040441

10.1007/BF02563820

10.1055/s-2007-1011815

10.1159/000180820

10.7326/0003-4819-104-5-648

10.1136/bmj.291.6495.574

10.1136/thx.45.8.573

Crilly RG, 1978, Hormonal status in normal, osteoporotic and corticosteroid‐treated postmenopausal women., J R Soc Med, 71, 733, 10.1177/014107687807101006

10.1016/0039-128X(78)90074-0

10.1002/jbmr.5650110516

10.1002/art.1780240705

10.1007/BF00542348

Montecucco C, 1992, Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids., J Rheumatol, 19, 1895

10.1007/BF02407171

10.1007/BF02405325

10.1007/BF02405356

10.1007/BF00582160

Messina OD, 1992, et al. Effect of low doses of deflazacort vs. prednisone on bone mineral content in premenopausal rheumatoid arthritis., J Rheumatol, 19, 1520

10.1016/S0954-6111(97)90109-8

10.1007/s004670050308

10.1002/art.1780340306

Krogsgaard MR, 1995, A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica., J Rheumatol, 22, 1660

Loftus J, 1991, Randomized, double‐blind trial of deflazacort vs. prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone‐sparing effect of deflazacort., Pediatrics, 88, 428

David J, 1992, Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 2 years with deflazacort., Clin Exp Rheumatol, 10, 621

10.1097/00124743-199706000-00005

10.2165/00003495-199550020-00008

10.2165/00003495-199550050-00006

10.1111/j.1365-2036.1994.tb00340.x

10.1056/NEJM199208273270908

10.1016/8756-3282(94)90815-X

10.1093/rheumatology/33.4.348

Roux C, 1998, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid‐induced bone loss. Ciblos Study Group., J Clin Endocrinol Metab, 83, 1128, 10.1210/jcem.83.4.4742

10.1056/NEJM199708073370603

10.1007/s002239900334

10.1046/j.1365-2796.1997.00210.x

Adachi JD, 1994, Intermittent cyclic therapy with etidronate in the prevention of corticosteroid‐induced bone loss., Can J Rheumatol, 21, 1922

10.1016/S0002-9343(99)80154-5

10.3109/03009749609103760

10.1136/thx.53.5.351

Reid IR King AR Alexande CJ Ibbertson HK. Prevention of steroid‐induced osteoporosis with (3‐amino‐hydroxypropylidene)‐1 1‐disphosphonate (APD).Lancet1988; i: 143–6.

10.1002/jbmr.5650050611

10.1002/jbmr.5650070909

10.1002/art.1780371014

Reid IR, 1996, Testosterone therapy in glucocorticoid‐treated men., Arch Intern Med, 156, 1173, 10.1001/archinte.1996.00440100065008

10.1016/8756-3282(95)00441-6

10.1111/j.1365-2265.1994.tb03929.x

Gram J, 1991, Increased serum concentrations of type‐I procollagen C‐terminal propeptide and osteocalcin during a short course of calcitriol administration to adult male volunteers., Acta Endocrinol Copenh, 125, 609

Adachi JD, 1996, Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup., J Rheumatol, 23, 995

10.7326/0003-4819-125-12-199612150-00004

10.1007/BF02565124

10.1093/rheumatology/36.2.255

10.1007/BF02529727

10.1136/thx.49.11.1099

10.1007/BF02652565

10.1007/BF01623657

10.1007/BF01623943

10.1136/ard.56.6.357

10.1007/BF00310253

10.1016/S0022-3476(94)70193-8

Kreipe RE, 1992, Bone of today. bones tomorrow., Am J Dis Child, 146, 22

10.1097/01241398-199101000-00011

Dolan P Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population.Osteoporos Int1998 (in press).

Thông tin
Thông tin xuất bản

Journal of Internal Medicine

Tập 244 Số 4

271-292

Thông tin tác giả